###### What is known about the subject?

-   Head circumference is considered a reliable assessment of the volume of the underlying brain.

-   The recent outbreak of microcephaly associated with congenital Zika virus infection first identified in Brazil has drawn greater attention to Zika virus around the world.

###### What this study adds?

-   A high prevalence of microcephaly was identified in a predominantly Cantonese birth cohort in China with no documented evidence of Zika virus infection.

-   In utero exposure to teratogens and TORCH (*Toxoplasma gondii*, rubella virus, cytomegalovirus, herpes simplex virus) agents were associated with a higher risk of absolute microcephaly.

-   This study reinforces the applicability of a customised definition of absolute and relative microcephaly.

Introduction {#s1}
============

Microcephaly in the newborn is characterised by a disproportionately small head circumference (HC) for gestational age and may be categorised as *absolute* (asymmetrical growth retardation---where the HC is reduced to a greater extent than length and weight) or *relative* (symmetrical growth retardation---where the HC, the length and weight are reduced to a similar degree).[@R1] Despite considerable advances in case ascertainment, microcephaly remains a heterogeneous group of primarily neurological deficits.[@R2] HC is considered a reliable assessment of the volume of the underlying brain. WHO currently recommends the Intergrowth-21st criteria to classify HC if the gestational age is known.[@R7] However, there exist a number of methods for microcephaly ascertainment, including \>2 SD or \>3 SD below mean HC. In addition, ethnicity is another factor to consider, as norms for HC may depend on the population for whom the standard was created. As such, prevalence rates of microcephaly vary greatly by country, ethnicity and region or even birth hospital where the standards and case ascertainment methods are used.[@R10]

Unlike intrauterine growth restriction (IUGR) or small for gestational age, the underlying cause/aetiology for microcephaly is reported to be largely genetic or unknown.[@R2] Devakumar *et al* recently summarised several major maternal infections such as cytomegalovirus, herpes simplex virus (HSV), rubella virus, *Toxoplasma gondii* and Zika virus as known causes for congenital microcephaly.[@R15] In high-income countries, however, microcephaly was reportedly due to non-infectious causes.[@R10] A recent study of hospital birth data from Quebec, Canada, reported that the strongest non-genetic risk factor for microcephaly was TORCH (ie, *T. gondii*, rubella virus, cytomegalovirus, HSV) infection with a 32-fold risk, and in utero exposure to teratogens (ie, alcohol or drug use) with an over threefold risk of microcephaly despite an observed low prevalence.[@R13] The recent outbreak of microcephaly associated with congenital Zika virus infection, first identified in Brazil, has drawn attention to Zika virus because the outbreak led to congenital microcephaly in a susceptible population, affecting a very large number of infants.[@R20]

The Intergrowth-21st Project recently published HC standards based on a low-risk population of fetuses and newborn infants.[@R7] According to the standard, 9.8% of singleton live births from 2009 to 2012 in Guangzhou are below the third centile of HC, and 12.1% are in the third to the 10th centile.[@R23] This surprisingly high rate of small HC calls for close assessment of this population. In this retrospective cohort study, we aimed to characterise microcephalic infants, to identify risk factors (maternal factors or antenatal antecedents) for microcephaly and to assess the effects of microcephaly on neonatal outcomes.

Methods {#s2}
=======

Guangzhou Maternal-Fetal Care Database {#s2-1}
--------------------------------------

This database was created following the Canadian perinatal health surveillance and research data source guidelines[@R24] and contains all records of hospital deliveries (≥22 weeks of gestation) at Metropolitan Guangzhou Tertiary Care Centre for Pregnant Women. The hospitalisation records are collated by trained medical record personnel using standardised definitions[@R24] and contain information on gestational age (ultrasound-based estimate), plurality, birth weight, laboratory tests, ultrasounds, maternal and newborn conditions (principal diagnosis and up to 24 secondary diagnostic fields) during antenatal hospital visits and the obstetric delivery/neonatal admission. Data collection began in 2008, and the data are routinely checked for accuracy and completeness.[@R25] Information on maternal demographic characteristics (eg, ethnicity, birth place, education, occupation, current residence, age, parity), conception method (natural, in vitro fertilisation (IVF)), prenatal care or medical visits, laboratory tests, neonatal conditions including Apgar scores, length of hospital stay and discharge status is recorded in the database.[@R23] Medical conditions, diagnoses, and diagnostic, therapeutic and surgical procedures among mothers and newborns were coded using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision (ICD-10, WHO). Newborn birth weight (gram), femur length (centimetre), HC (centimetre) are all measured and recorded at birth. In addition, all delivering mothers and newborns (including stillbirths) are linked using mother--newborn dyad numbers assigned at birth. Stillbirths and live births with central nervous system anomalies were excluded from this study population to minimise potential confounding of the assessment of small HC.

Identification of microcephaly {#s2-2}
------------------------------

We analysed three primary outcomes, including absolute, relative and mild microcephaly ([figure 1](#F1){ref-type="fig"}). To categorise the outcomes, we first identified all singleton infants between 33 and 42 weeks' gestation who satisfied the Intergrowth-21st standard for microcephaly. We used the Intergrowth criteria to define microcephaly as an HC z-score \>2 SD below the mean,[@R7] and further characterised infants who satisfied the criteria into four subtypes: (1) absolute microcephaly defined as an HC \>3 SD below the mean with 'normal' (ie, ≥3rd centile) birth weight; (2) relative microcephaly defined as an HC \>3 SD below the mean with 'low' (ie, \<3rd centile) birth weight and (3) mild microcephaly infants whose HC was between 2 and 3 SD below the mean with 'normal' birth weight; (4) infants with both HC ≤2 SD below the mean and normal birth weight were defined as normocephaly and used as the comparison group ([figure 1](#F1){ref-type="fig"}).

![Flow chart detailing identification of microcephaly in Guangzhou tertiary care centre for pregnant women. BW, birth weight; CNS, central nervous system; HC, head circumference.](bmjpo-2019-000470f01){#F1}

Absolute and relative microcephaly both captured HC \>3 SD below the mean, but distinguished infants on body size or birth weight. Absolute microcephaly included infants whose birth weight was ≥ 3rd centile of the distribution. In contrast, relative microcephaly included infants whose birth weight was ≤3rd centile of the distribution. Relative microcephaly is generally more severe than absolute microcephaly and may be a marker of growth restriction overall. The category mild microcephaly was a variant of absolute microcephaly, capturing infants categorised as microcephalic by Intergrowth-21st standards, but with an HC \>2 SD of the mean and birth weight ≥3rd centile. Our hypothesis was that risk factors, birth outcomes and neonatal morbidity and mortality for absolute, relative and mild microcephaly may vary.

Maternal factors and antenatal antecedents {#s2-3}
------------------------------------------

We characterised maternal demographics and risk factors for the three types of microcephaly. We considered maternal age at conception (\<25, 25--29, 30--34 and ≥35 years), mother's ethnicity (Cantonese women vs women migrated from other provinces of China), parity (first vs ≥second child), conception method (IVF vs natural), pregnancy condition (ie, pre-existing hypertension, gestational hypertension, pre-eclampsia/eclampsia, gestational and pregestational diabetes mellitus),[@R17] exposure to teratogens (ie, maternal use of substances or behavioural risk factors) including prenatal and/or perinatal use of alcohol, cigarette or medicinal or other illicit or therapeutic drugs[@R13] and TORCH infections during pregnancy. In addition, we included congenital heart defects and other anomalies as the former has been strongly associated with microcephaly.[@R3] We used ICD-10 codes to document whether women had these conditions during pregnancy and/or at the time of delivery ([online supplementary appendix table 1](#SP1){ref-type="supplementary-material"}). In addition, we defined three maternal educational levels as university or college (\>12 years of school), high school (10--12 years) and elementary school (\<10 years). We used educational attainment as a proxy for socioeconomic status (SES) and family wealth.
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We assessed infant status or poor birth outcomes (preterm birth, 1 min and 5 min Apgar scores) and respiratory distress syndrome and comorbidities (necrotising enterocolitis, intracranial haemorrhage, bronchopulmonary dysplasia, birth hypoxia, seizure, feeding difficulties). We also assessed mean length of stay after delivery, including \>7 or \>10 days of hospital stay. We determined neonatal in-hospital mortality according to discharge summaries ([online supplementary appendix table 1](#SP1){ref-type="supplementary-material"}).

Statistical analysis {#s2-4}
--------------------

We calculated prevalence rates of absolute, relative and mild microcephaly per 1000 live births. We used simple logistic regression to estimate crude ORs, and multiple logistic regression to estimate adjusted ORs (AORs) and 95% CIs for the association between maternal risk factors and absolute, relative or mild microcephaly. Finally, we assessed associations between microcephaly as the fetal exposure and poor birth outcomes or comorbidities in models adjusted for infant gender, parity, maternal age, ethnicity, education, TORCH agents, exposure to teratogens, pre-eclampsia, diabetes mellitus and chronic illness. All variables were entered simultaneously in multiple logistic regression models. A modelling selection process was not applied. In addition, we tested for multicollinearity among independent variables.[@R28] Statistical analyses were undertaken with SAS version 9.4 (SAS Institute, Cary, North Carolina) software.

Patient and public involvement {#s2-5}
------------------------------

As this study was based on predesigned and ongoing collection of birth hospitalisation data for newborns and the mothers, no patients were involved in setting the research question or outcome measures, nor were they involved in developing plans for implementation of the study. No patients were asked to comment on the study design or were consulted to interpret the results. Patients were not invited to contribute to writing or editing this document for readability or accuracy.

Results {#s3}
=======

Among 45 663 singleton live births of 33 to 42 weeks' gestation, 3.1% (n=1398) had birth weight \<3rd centile and 2.8% (n=1283) had femur length \<3rd centile. The majority (85.2%) of mothers were of Cantonese origin and 81.2% were primiparous.

A total of 2709 liveborns had HC \>2 SD below the mean, resulting in an overall prevalence of microcephaly of 59.3 per 1000 infants. After excluding the \<3rd centile for birth weight, there remained 2102 infants (46.0 per 1000) with mild 'absolute' microcephaly. A total of 240 'severe' microcephaly infants were identified, yielding an overall prevalence of 5.2 per 1000 live births. There were 129 infants with absolute microcephaly (2.8 per 1000) and 111 infants with relative microcephaly (2.4 per 1000) ([figure 1](#F1){ref-type="fig"}).

Absolute microcephaly was associated with maternal exposure to teratogens (AOR 4.2, 95% CI 2.0 to 8.8) and TORCH agents (AOR 3.2, 95% CI 1.1 to 9.5). In addition, IUGR and pre-eclampsia were, respectively, associated with a nearly fivefold and threefold increased risk of absolute microcephaly ([table 1](#T1){ref-type="table"}). Relative microcephaly was significantly associated with IUGR (AOR 20.2, 95% CI 12.2 to 33.5), pre-eclampsia/eclampsia (AOR 5.3, 95% CI 3.1 to 8.9), TORCH agents (AOR 3.0, 95% CI 1.1 to 7.9) and elementary school or lower education (AOR 2.6, 95% CI 1.6 to 4.1). Relative microcephaly was significantly associated with congenital heart defects (AOR 3.4, 95% CI 1.6 to 7.1) ([table 2](#T2){ref-type="table"}).

###### 

Maternal characteristics and factors and risk of absolute microcephaly in the offspring

  --------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                             Absolute microcephaly   Non-microcephaly   Prevalence per 1000   OR\                    
                                                                                                              95% CI                 
  ------------------------------------------ ----------------------- ------------------ --------------------- ---------------------- ---------------------
  Maternal age (years)                                                                                                               

   \<25                                      31                      5 244              5.9                   2.14 (1.33 to 3.44)    1.51 (0.90 to 2.53)

   25--29                                    51                      18 263             2.8                   1.01 (0.66 to 1.54)    0.92 (0.59 to 1.41)

   30--34                                    38                      13 730             2.8                   1.00 (reference)       1.00 (reference)

   ≥35                                       9                       6 899              1.3                   0.47 (0.23 to 0.98)    0.47 (0.23 to 0.99)

  Education                                                                                                                          

   University/college                        61                      26 775             2.3                   1.00 (reference)       1.00 (reference)

   High school                               22                      6 576              3.3                   1.47 (0.90 to 2.39)    1.27 (0.72 to 2.11)

   Elementary school                         46                      10 785             4.2                   1.87 (1.28 to 2.75)    1.57 (1.02 to 2.40)

  Primiparity                                105                     35 902             2.9                   1.00 (0.64 to 1.56)    1.42 (0.87 to 2.32)

  Cantonese ethnicity                        110                     37 591             2.9                   1.01 (0.62 to 1.64)    0.95 (0.57 to 1.56)

  IVF conception                             7                       2 576              2.9                   0.93 (0.43 to 1.99)    1.12 (0.51 to 2.46)

  Congenital heart disease                   6                       445                13.5                  4.79 (2.10 to 10.93)   2.33 (0.97 to 5.63)

  Other congenital anomalies in offspring†   3                       440                6.8                   2.37 (0.75 to 7.46)    1.33 (0.38 to 4.67)

  Intrauterine growth restriction            6                       212                27.5                  10.1 (4.41 to 23.2)    4.92 (2.04 to 11.9)

  Maternal anomalies                         3                       390                7.6                   2.67 (0.85 to 8.43)    2.34 (0.73 to 7.53)

  Diabetes mellitus                          10                      5311               1.9                   0.61 (0.32 to 1.17)    0.75 (0.39 to 1.44)

  Pre-eclampsia                              8                       863                9.2                   3.32 (1.62 to 6.80)    2.64 (1.25 to 5.59)

  Chronic illness                            24                      6303               3.8                   1.37 (0.88 to 2.14)    1.43 (0.91 to 2.24)

  Teratogens                                 8                       626                12.6                  4.60 (2.24 to 9.44)    4.18 (1.98 to 8.77)

  TORCH agents‡                              4                       324                12.2                  4.33 (1.59 to 11.8)    3.21 (1.09 to 9.49)

  Genital/reproductive infections            1                       688                1.5                   0.49 (0.07 to 3.53)    0.57 (0.07 to 4.16)

  Overall                                    129                     44 136             2.9                                           
  --------------------------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for infant birth year.

†Exclusive of congenital heart disease and CNS anomalies.

‡Latent *Toxoplasma gondii* only.

CNS, central nervous system; IVF, in vitro fertilisation; TORCH, *Toxoplasma gondii*, rubella virus, cytomegalovirus, herpes simplex virus.

###### 

Maternal characteristics and factors and risk of relative microcephaly in the offspring

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                             Relative microcephaly   Non-microcephaly   Prevalence per 1000   OR\                   
                                                                                                              95% CI                
  ------------------------------------------ ----------------------- ------------------ --------------------- --------------------- ---------------------
  Maternal age (years)                                                                                                              

   \<25                                      24                      5463               4.4                   2.05 (1.18 to 3.42)   1.26 (0.69 to 2.28)

   25--29                                    35                      18 802             1.9                   0.85 (0.52 to 1.38)   0.91 (0.55 to 1.51)

   30--34                                    31                      14 148             2.2                   1.00 (reference)      1.00 (reference)

   ≥35                                       21                      7139               2.9                   1.34 (0.77 to 2.34)   1.08 (0.61 to 1.93)

  Education                                                                                                                         

   University/college                        37                      27 512             1.3                   1.00 (reference)      1.00 (reference)

   High school                               19                      6765               2.8                   2.09 (1.20 to 3.63)   1.70 (0.95 to 3.03)

   Elementary school                         55                      11 275             4.9                   3.63 (2.39 to 5.51)   2.58 (1.60 to 4.08)

  Primiparity                                85                      37 013             2.3                   0.75 (0.49 to 1.17)   1.34 (0.80 to 2.25)

  Cantonese ethnicity                        94                      38 808             2.4                   0.96 (0.57 to 1.61)   1.11 (0.65 to 1.90)

  IVF conception                             8                       2659               3.0                   1.25 (0.61 to 2.58)   1.36 (0.64 to 2.90)

  Congenital heart disease                   12                      513                22.9                  10.6 (5.8 to 19.5)    3.41 (1.64 to 7.08)

  Other congenital anomalies in offspring†   4                       480                8.3                   3.51 (1.29 to 9.56)   1.08 (0.35 to 3.33)

  Intrauterine growth restriction            33                      402                75.9                  47.5 (31.3 to 72.2)   20.2 (12.2 to 33.5)

  Maternal anomalies                         2                       420                4.7                   1.97 (0.49 to 8.01)   1.23 (0.28 to 5.35)

  Diabetes mellitus                          14                      5484               2.5                   1.06 (0.61 to 1.85)   1.05 (0.58 to 1.84)

  Pre-eclampsia                              27                      1055               25.0                  13.6 (8.75 to 21.0)   5.28 (3.13 to 8.90)

  Chronic illness                            15                      6576               2.1                   0.86 (0.49 to 1.50)   0.71 (0.40 to 1.25)

  Teratogens                                 5                       664                7.5                   3.19 (1.30 to 7.85)   1.32 (0.48 to 3.60)

  TORCH agents‡                              6                       371                15.9                  6.96 (3.04 to 15.9)   2.96 (1.10 to 7.94)

  Genital/reproductive infections            1                       719                1.4                   0.57 (0.08 to 4.07)   0.41 (0.06 to 3.07)

  Overall                                    111                     45 552             2.4                                          
  -------------------------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for infant birth year.

†Exclusive of congenital heart disease and CNS anomalies.

‡Latent *Toxoplasma gondii* only.

CNS, central nervous system; IVF, in vitro fertilisation; TORCH, *Toxoplasma gondii*, rubella virus, cytomegalovirus, herpes simplex virus.

In multiple logistic regression, mothers' Cantonese origin (AOR 1.45, 95% CI 1.25 to 1.68), primiparity (AOR 1.7, 95% CI 1.5 to 2.0) and young maternal age were associated with a higher risk of mild microcephaly. Maternal age \<25 years was associated with 30% higher risk of mild microcephaly (AOR 1.3, 95% CI 1.1 to 1.4) versus 30--34 years. IVF conception was associated with a 22% decreased risk of mild microcephaly ([table 3](#T3){ref-type="table"}). Multicollinearity tests did not show meaningful evidence of collinearity between exposure variables.

###### 

Maternal characteristics and factors associated with risk of mild microcephaly

  ---------------------------------------------------------------------------------------------------------------------------------------------------
  Characteristic                             Mild microcephaly   Normocephaly   Prevalence rate per 100   OR\                   
                                                                                                          95% CI                
  ------------------------------------------ ------------------- -------------- ------------------------- --------------------- ---------------------
  Maternal age (years)                                                                                                          

   \<25                                      312                 4932           6.0                       1.37 (1.19 to 1.58)   1.29 (1.06 to 1.42)

   25--29                                    988                 17 275         5.4                       1.24 (1.12 to 1.38)   1.13 (1.01 to 1.25)

   30--34                                    605                 13 125         4.4                       1.00 (reference)      1.00 (reference)

   ≥35                                       197                 6702           2.9                       0.64 (0.54 to 0.75)   0.54 (0.41 to 0.72)

  Education                                                                                                                     

   University/college                        1311                25 464         4.9                       1.00 (reference)      1.00 (reference)

   High school                               312                 6 64           4.7                       0.97 (0.85 to 1.10)   0.99 (0.87 to 1.13)

   Elementary school                         479                 10 306         4.6                       0.90 (0.81 to 1.01)   1.02 (0.91 to 1.14)

  Primiparity                                1850                34 052         5.2                       1.72 (1.51 to 1.97)   1.73 (1.50 to 2.01)

  Cantonese ethnicity                        1888                35 703         5.0                       1.56 (1.36 to 1.81)   1.45 (1.25 to 1.68)

  IVF conception                             89                  2 487          3.5                       0.72 (0.57 to 0.89)   0.78 (0.65 to 0.96)

  Congenital heart disease                   22                  423            4.9                       1.04 (0.68 to 1.60)   0.89 (0.57 to 1.38)

  Other congenital anomalies in offspring†   25                  415            5.7                       1.21 (0.80 to 1.81)   1.23 (0.81 to 1.86)

  Intrauterine growth restriction            40                  172            18.8                      4.72 (2.34 to 6.68)   4.48 (3.14 to 6.40)

  Maternal anomalies                         15                  375            3.9                       0.80 (0.48 to 1.34)   0.80 (0.48 to 1.35)

  Diabetes mellitus                          216                 5095           4.1                       0.83 (0.72 to 0.96)   0.96 (0.83 to 1.11)

  Pre-eclampsia                              44                  819            5.1                       1.08 (0.79 to 1.46)   1.10 (0.81 to 1.51)

  Chronic illness                            276                 6027           4.4                       0.90 (0.79 to 1.03)   0.92 (0.81 to 1.05)

  Teratogens                                 35                  591            5.6                       1.18 (0.84 to 1.67)   1.22 (0.86 to 1.73)

  TORCH agents‡                              11                  313            3.4                       0.70 (0.38 to 1.28)   0.70 (0.38 to 1.28)

  Genital/reproductive infections            19                  669            2.8                       0.56 (0.36 to 0.89)   0.66 (0.42 to 1.06)

  Overall                                    2102                42 034         4.8                                              
  ---------------------------------------------------------------------------------------------------------------------------------------------------

\*Adjusted for infant birth year.

†Exclusive of congenital heart disease and CNS anomalies.

‡Latent *Toxoplasma gondii* only.

CNS, central nervous system; IVF, in vitro fertilisation; TORCH, *Toxoplasma gondii*, rubella virus, cytomegalovirus, herpes simplex virus.

Compared with normocephaly, absolute microcephaly was associated with a significantly higher odds of neonatal seizure (AOR 8.7, 95% CI 1.1 to 69.1), preterm birth (AOR 2.0, 95% CI 1.2 to 3.2), 1 min Apgar scores \<8 (AOR 2.0, 95% CI 1.1 to 4.1) and longer in-hospital stay (AOR 3.2, 95% CI 1.9 to 5.4). In contrast, relative microcephaly was associated with poor birth outcomes and neonatal morbidity, including significantly higher preterm birth (AOR 1.7, 95% CI 1.0 to 2.7), 1 min Apgar scores \<8 (AOR 2.6, 95% CI 1.4 to 4.9), 5 min Apgar scores \<8 (AOR 3.6, 95% CI 1.2 to 10.7), intracranial haemorrhage (AOR 7.0, 95% CI 2.4 to 20.1), bronchopulmonary dysplasia (AOR 10.1, 95% CI 1.2 to 82.2), birth hypoxia (AOR 2.6, 95% CI 1.3 to 5.3), longer in-hospital stay (AOR 4.7, 95% CI 3.0 to 7.5) and higher neonatal in-hospital mortality (AOR 11.7, 95% CI 4.3 to 31.7) compared with normocephaly ([table 4](#T4){ref-type="table"}). However, infants with mild microcephaly had good birth outcomes overall with comparable neonatal comorbidity and length of in-hospital stay relative to normocephaly. It is noteworthy that mild microcephaly was associated with lower odds of preterm birth ([table 5](#T5){ref-type="table"}).

###### 

Comorbidity and poor birth outcome for absolute and relative microcephaly versus normocephaly

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Mortality/morbidity              Absolute microcephaly\   Non-absolute microcephaly\   AOR\* (95% CI)        Relative microcephaly\   Non-relative microcephaly\   AOR\* (95% CI)
                                   (N=129)                  (N=44 136)                                         (N=111)                  (N=45 552)                   
  -------------------------------- ------------------------ ---------------------------- --------------------- ------------------------ ---------------------------- ---------------------
  In-hospital mortality            0                        90 (2.0)†                    NS                    5 (45.0)                 96 (2.1)                     11.7 (4.31 to 31.7)

  Preterm (33--36 weeks)           22 (170.5)               3550 (80.4)                  1.96 (1.20 to 3.23)   31 (279.3)               4171 (91.6)                  1.67 (1.02 to 2.74)

  1 min Apgar score \<8            7 (54.3)                 948 (21.5)                   1.98 (1.06 to 4.09)   13 (117.1)               1083 (23.8)                  2.61 (1.41 to 4.87)

  5 min Apgar score \<8            0                        147 (3.3)†                   NS                    4 (36.0)                 160 (3.5)                    3.61 (1.21 to 10.7)

  Necrotising enterocolitis        0                        52 (1.2)                     NS                    1 (9.0)                  60 (1.3)                     2.40 (0.31 to 18.0)

  Intracranial haemorrhage         1 (7.8)                  134 (3.0)                    1.93 (0.26 to 14.2)   4 (36.0)                 154 (3.4)                    6.95 (2.41 to 20.1)

  Bronchopulmonary dysplasia       0                        22 (0.5)†                    NS                    1 (9.0)                  24 (0.5)                     10.1 (1.24 to 82.2)

  Birth hypoxia                    4 (31.0)                 629 (14.3)                   1.62 (0.59 to 4.47)   10 (90.1)                710 (15.6)                   2.64 (1.31 to 5.31)

  Feeding difficulties             9 (69.8)                 2346 (53.2)                  1.41 (0.71 to 2.79)   5 (45.1)                 2115 (46.4)                  0.21 (0.03 to 1.50)

  Signs of seizure                 1 (7.8)                  29 (0.7)                     8.76 (1.11 to 69.1)   0                        31 (0.7)†                    NS

  Sepsis of newborn                0                        95 (2.2)†                    NS                    1 (9.0)                  105 (2.3)                    1.69 (0.22 to 13.0)

  Respiratory distress syndrome    1 (7.8)                  449 (10.2)                   0.61 (0.08 to 4.43)   15 (135.1)               516 (11.3)                   7.07 (3.87 to 12.9)

  Length of stay \>10 days ‡       19 (147.3)               1877 (42.5)                  3.23 (1.94 to 5.39)   35 (315.3)               2232 (49.0)                  4.47 (3.01 to 7.46)

  Length of stay (mean±SD, day)‡   5.9±6.8\*\*\*            4.0±3.2                                            10.1±10.0\*\*\*          4.1±3.5                       
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*\*\*P\<0.001.

\*Models contain absolute or relative microcephaly as the exposure, and birth issues as outcomes, and are adjusted for infant gender, parity, maternal age, ethnicity, education, TORCH agents, exposure to teratogens, pre-eclampsia, diabetes mellitus and chronic illness.

†Fisher's exact test is applied, and NS denotes non-significance.

‡Infant in-hospital deaths were excluded for the calculation of length of stay.

AOR, adjusted OR; TORCH, *Toxoplasma gondii*, rubella virus, cytomegalovirus, herpes simplex virus.

###### 

Comorbidity and poor birth outcome for mild microcephaly versus normocephaly

  --------------------------------------------------------------------------------------------------------------------------------
  Mortality/morbidity             Mild microcephaly\   Normocephaly\   OR                                    
                                  (n=2102)             (n=42 034)                                            
  ------------------------------- -------------------- --------------- -------- ------ --------------------- ---------------------
  In-hospital mortality           5                    2.0             85       2.0    1.18 (0.48 to 2.90)   1.21 (0.49 to 3.00)

  Preterm (33--36 weeks)          80                   38.4            3470     82.6   0.45 (0.36 to 0.55)   0.45 (0.35 to 0.56)

  1 min Apgar score \<8           45                   21.4            939      22.3   0.96 (0.71 to 1.30)   0.98 (0.72 to 1.33)

  5 min Apgar score \<8           6                    2.9             141      3.4    0.85 (0.38 to 1.93)   0.83 (0.37 to 1.90)

  Necrotising enterocolitis       3                    1.6             49       1.2    1.23 (0.38 to 3.93)   1.26 (0.39 to 4.05)

  Intracranial haemorrhage        9                    3.2             125      3.0    1.44 (0.73 to 2.84)   1.58 (0.80 to 3.15)

  Bronchopulmonary dysplasia      1                    0.4             21       0.5    0.95 (0.13 to 7.08)   1.03 (0.14 to 8.04)

  Birth hypoxia                   35                   16.2            594      14.1   1.18 (0.84 to 1.67)   1.21 (0.85 to 1.71)

  Feeding difficulties            103                  55.0            2243     53.4   0.91 (0.75 to 1.12)   0.89 (0.72 to 1.09)

  Signs of seizure                1                    0.5             27       0.7    0.74 (0.33 to 5.63)   0.76 (0.34 to 5.66)

  Sepsis of newborn               5                    2.4             90       2.1    1.11 (0.45 to 2.74)   1.09 (0.44 to 2.68)

  Respiratory distress syndrome   14                   6.3             435      10.3   0.64 (0.38 to 1.09)   0.71 (0.42 to 1.22)

  Length of stay \>7 days†        197                  93.7            3916     93.2   1.01 (0.87 to 1.17)   1.07 (0.91 to 1.39)

  Length of stay (mean±SD, day)   3.84±3.66            3.97±3.21       P=0.11                                
  --------------------------------------------------------------------------------------------------------------------------------

\*Models contain mild microcephaly (vs normocephaly) as the exposure, and birth issues as outcomes, and are adjusted for infant gender, parity, maternal age, ethnicity, education, TORCH agents, exposure to teratogens, pre-eclampsia, diabetes mellitus and chronic illness.

†Infant in-hospital deaths were excluded for the calculation of length of stay.

TORCH, *Toxoplasma gondii*, rubella virus, cytomegalovirus, herpes simplex virus.

Discussion {#s4}
==========

We found an unexpectedly high rate of small HC, including absolute, relative and mild microcephaly, in a predominately Cantonese liveborn cohort in southern China. We analysed several markers capturing the severity and degree of microcephaly. Primiparity, pre-eclampsia, younger maternal age, TORCH agents and lower education attainment were all associated with an increased risk of smaller HC, with variations across absolute, relative and mild microcephaly. Some of the associations may be explained by a large number of infants born to Cantonese mothers (eg,[table 3](#T3){ref-type="table"}), whose statute is smaller than women in other parts of China,[@R29] although the underlying relationship is complex. In addition to well-established IUGR,[@R2] factors such as genetics/ethnicity, nutrients (ie, excess seafood) and heavy air pollution in metro Guangzhou may relate to the increased small HC.[@R16] Moreover, our results suggest that absolute and relative microcephaly are distinct, with relative microcephaly associated with a wide range of adverse neonatal outcomes given the significant effect of IUGR, and absolute microcephaly associated with adverse neurological outcomes but fewer comorbidities overall. Mild microcephaly differed little from normocephaly with respect to comorbidities, in-hospital mortality and hospital length of stay. In this study, we were initially concerned by absolute microcephaly as these children are more likely to have future intellectual disability.[@R1]

Microcephaly is a clinical sign, not a diagnosis.[@R2] Microcephaly is usually defined as an occipitofrontal HC of 2 or 3 SD below the mean on age-matched and sex-matched curves.[@R2] Primary or congenital microcephaly is usually identified during neonatal examinations before birth hospital discharge, but may also be detected with measurements of HC in utero during ultrasound screening.[@R33] According to US surveillance data, the prevalence of congenital microcephaly varies from 2 to 12 cases per 10 000 infants.[@R11] In one study, the prevalence of microcephaly was 8.7 per 10 000 live births based on 30 birth defect surveillance programme covering 11 million live births in the USA.[@R16] In Europe, the overall prevalence is approximately 2.6 to 2.9 per 10 000 live births; however, rates vary greatly between countries.[@R10] A recent study from Quebec, Canada, reported an overall microcephaly prevalence of 4.1 per 10 000 live births between 1989 and 2012, fluctuating between 3.0 and 5.3 per 10 000 annually.[@R13] However, these prevalence rates are from routine birth surveillance data and may be underestimated, as measurement of microcephaly is not based on standardised diagnostic criteria.[@R1] Different operational definitions of microcephaly make it difficult to evaluate rates across studies. Moreover, HC measurements could be more representative of congenital microcephaly recognised clinically[@R6] and have the advantage of allowing researchers to distinguish cases as relative, absolute or mild.

Our results suggested that IVF was associated with an increased HC compared with natural conception. Previous studies report conflicting findings on fetal growth and HC following assisted reproductive techniques.[@R34] Further study including characteristics such as origin/ethnicity of sperm/egg donors may be helpful for clarification. The association of in utero exposure to teratogens with absolute microcephaly was, however, consistent with previous studies.[@R13] Exposures to teratogens or substances such as cocaine, opioids and alcohol are known risk factors for microcephaly[@R4] and other neurological developmental abnormalities.[@R27] Another recent study from Quebec, Canada, found that neonatal abstinence syndrome (a proxy for exposure to maternal opioids exposure) was associated with a 16-fold higher risk (adjusted risk ratio 16.4, 95% CI 9.4 to 28.6) of congenital microcephaly.[@R26]

Maternal exposure to TORCH agents and pre-eclampsia appeared to increase the risk of relative microcephaly ([table 2](#T2){ref-type="table"}). Previous studies have already linked severe fetal growth restriction to pre-eclampsia and TORCH agents including *T. gondii*.[@R15] According to ICD codes, we most likely captured maternal latent TORCH infections, in particular, for *T. gondii*.[@R39] Other TORCH agents were not included in our data despite evidence that outbreaks of chikungunya and dengue occurred in the study areas.[@R41]*T. gondii* infection during pregnancy has also been found to play a role in absolute microcephaly, aligning with our study results.

We observed significantly increased risks of neonatal seizure, preterm birth and poor 1 min Apgar scores for absolute microcephaly, reflecting a possible higher risk of neurological developmental abnormality and adverse intellectual prognosis.[@R1] Our findings reflect great variations among absolute, relative and mild microcephalic infants despite no follow-up data on their future neurological development.

There are several limitations inherent to our study. First, there currently is no standardised definition or classification for microcephaly. Hospital discharge data may underestimate the prevalence, as many cases may not be reported despite meeting the clinical definition of microcephaly. Second, selection bias could have occurred if women with high-risk pregnancies were more likely to deliver at a tertiary care centre. Our analysis is based on a single large tertiary hospital in Guangzhou metromunicipal region rather than a population-based setting. We had consistent measurements of HC at birth, but follow-up information on head growth after discharge from hospital was not available. Although there may be issues with generalisability, our study adds to the portrait of microcephaly in China, using a multiyear cohort of hospital live births with no documented evidence of Zika. In addition, we could not adjust for indicators of SES apart from education.

In conclusion, we found a high prevalence of absolute, relative and mild microcephaly in a predominantly Cantonese birth cohort in China. Several risk factors including in utero exposure to teratogens, IUGR and TORCH agent played a role in the elevated rate of microcephaly. Relative and absolute microcephaly were associated with diverse risk factor profiles and neonatal outcomes, but these factors were not related to mild microcephaly. Our findings suggest that in addition to pre-eclampsia, in utero exposure to teratogens and infectious agents were the largest contributors to absolute microcephaly. Preventable risk factors such as teratogens and TORCH agents highlight the importance of prenatal screening for abnormal fetal brain development. The high prevalence of relative microcephaly and associated poor outcomes at birth suggests that women of Cantonese origin merit closer clinical management and follow-up to maximise fetal head development during pregnancy.
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